BioAtla enters $40M SPV deal to advance Oz-V Phase 3; retains 65% ownership

BioAtla, Inc.

Total $40M from Inversagen AI for 35% of SPV units; initial $5M closing by Jan 30, 2026.
BioAtla retains 65% ownership of Oz-V across all solid tumor indications after transaction.
Proceeds fund Phase 3 trial for Oz-V in 2L+ OPSCC; enrollment expected to begin early 2026.
Related-party transaction: Chairman/CEO Dr. Jay Short and spouse are managers of Inversagen entities.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

BioAtla, Inc. entered into Investment Agreement with Inversagen AI, LLC and Alliance International Resources Corp. valued at aggregate $40 million (effective 2025-12-30).

Action: entry
Agreement: equity purchase
Counterparty: Inversagen AI, LLC and Alliance International Resources Corp.
Value: aggregate $40 million
Effective: 2025-12-30

Exact text from the filing

On December 30, 2025, BioAtla, Inc. (“the Company” or “BioAtla”) entered into an Investment Agreement (the “Investment Agreement”) with Inversagen AI, LLC, a Delaware limited liability company (“Inversagen AI”), and Alliance International Resources Corp., a Nevada corporation (“AIRC”).

View on SEC.gov

308 material agreements filed in the last 30 days. Browse all material agreements →

BioAtla, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-337646

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.